PPWR and Pharmaceutical Packaging: What Applies to Blister Foil in 2026

Quick answer: Pharmaceutical packaging is not broadly exempt from the PPWR. It gets narrow, safety-based carve-outs - mainly around recycled-content minimums - but recyclability design rules, substance restrictions, labelling, and the PPWR Declaration of Conformity still apply. Blister foil, including aluminium blister foil, is affected and is a top candidate for redesign toward mono-material formats.

If you work in pharma packaging, regulatory affairs, or quality, you've probably heard two conflicting things about the PPWR regulation: that pharma is "exempt," and that pharma is facing one of its biggest packaging overhauls in decades. Both statements are partly true, and the gap between them is exactly where compliance risk hides - especially for blister foil.

Here's what actually applies in 2026, explained plainly.

What Is the PPWR, in One Paragraph?

The Packaging and Packaging Waste Regulation - Regulation (EU) 2025/40, known as the PPWR - replaces the EU's 30-year-old Packaging Directive. It became generally applicable across all 27 EU member states on 12 August 2026. Unlike a directive, it applies directly, with no need for individual countries to transpose it into national law. It covers nearly every category of packaging placed on the EU market, including pharmaceutical packaging, and sets requirements around recyclability, substances of concern, labelling, minimisation, and reporting.

That single date - 12 August 2026 - is the one to remember. It's when the baseline obligations, including the requirement to hold a valid Declaration of Conformity, became operational. Further technical detail (recyclability grading, design-for-recycling criteria) is expected to roll out through 2028–2030.

PPWR Regulation Summary: The Core Obligations

Before getting into blister foil specifically, here's a PPWR regulation summary of what changed for packaging generally:

Substances of concern — new restrictions on PFAS and continued limits on heavy metals (lead, cadmium, mercury, hexavalent chromium).
Design for recycling — packaging must increasingly be designed to be recyclable, with detailed criteria being developed through delegated acts by around 2028.
Minimum recycled content — mandatory recycled-content thresholds for certain plastic packaging, phased in from 2030.
Packaging minimisation — the "empty space" rule limits packaging to what's genuinely needed to protect the product; over-packaging is now scrutinised.
Labelling — harmonised labelling requirements to support consumer sorting, expected from 2028.
Declaration of Conformity — documented proof that a given packaging format meets PPWR requirements.
Extended Producer Responsibility (EPR) — national EPR systems remain in place for registration, reporting, and fees, running alongside PPWR.

Is Pharmaceutical Packaging Exempt From PPWR?

This is the question everyone actually wants answered, so here it is directly: no, pharmaceutical packaging is not broadly exempt from PPWR. It receives targeted exemptions, not blanket relief.

Specifically, direct-contact packaging for medicinal products - the packaging that physically touches the drug product, like blister foil, vials, and bottles - is largely exempted from the minimum recycled content requirements. That's the exemption most people are referring to when they say pharma is "exempt." It exists because recycled content in direct-contact materials raises legitimate safety, purity, and contamination concerns that the regulation acknowledges.

What it does not exempt pharma from:

Substance restrictions (PFAS, heavy metals)
The Declaration of Conformity requirement
Packaging minimisation ("empty space") rules
Future recyclability design criteria for secondary and tertiary packaging
National EPR obligations

So, the honest framing is: pharmaceutical packaging carries PPWR exemptions for medicinal products that are real but narrow, concentrated almost entirely on recycled-content rules for immediate/primary packaging.

Where Blister Foil Fits In

Blister foil sits right at the centre of this ambiguity. It's classified as primary or immediate packaging, which is why it benefits from the recycled-content exemption. But that's where the good news ends.

Aluminium blister foil - the classic push-through format used across solid oral dosage forms - is a multi-material laminate: typically, PVC or PVC/PVDC on one side, aluminium foil on the lidding side. That layered, multi-material structure is precisely what recyclability-by-design rules are built to discourage. It's difficult to sort and difficult to recycle at end of life, which means it's a likely target once design-for-recycling criteria for pharma-adjacent formats mature.

Two things to watch:

1. Blisters are not automatically future-proof. The current exemption covers recycled content, not recyclability design obligations that are still being defined through 2028–2030. Regulatory commentary across the industry is consistent on this point: difficult-to-recycle formats like blisters may face pressure under future recyclability grading and fee structures, even if they stay exempt from recycled-content minimums.

2. The Declaration of Conformity applies now. Every packaging format on the EU market - blister foil included - needs a valid PPWR Declaration of Conformity as of 12 August 2026, documenting how that packaging meets applicable requirements. There is no transition period for this piece.

Mono-Material Blister Packaging: The Direction of Travel

This is why mono-material blister packaging has moved from "innovation project" to "compliance strategy" in pharma packaging conversations this year.

A mono-material blister - typically all-polypropylene (PP) or an all-aluminium structure - replaces the PVC/aluminium laminate with a single recyclable material family. The appeal is straightforward: single-material structures sort and recycle far more easily than laminates, positioning them favourably against whatever recyclability grading framework eventually emerges.

The complication is equally straightforward: pharmaceutical packaging isn't just packaging. It's a validated barrier system. Any material substitution can affect:

Moisture and oxygen barrier performance (critical for drug stability)
Sterility and tamper-evidence
Machine compatibility on existing blister lines
Stability data and shelf-life claims already filed with regulators
Artwork and regulatory submissions in every market the product is sold

That's why industry guidance is consistent: start evaluating mono-material and lightweighted alternatives now, not at the 2028–2030 deadlines, because pharma's validation, stability testing, and regulatory submission timelines run far longer than a typical packaging change cycle in other industries.

PPWR and PFAS: What Pharma Needs to Know

The PPWR regulation PFAS provisions are framed primarily around food-contact packaging, with a ban on intentionally added PFAS taking effect from 12 August 2026. Pharmaceutical packaging isn't the direct target of this specific rule, but two things matter here:

Pharma companies are increasingly adopting PFAS-free specifications anyway, both to stay ahead of scope creep and to align with broader chemical-safety expectations under Article 5 (substances of concern), which also keeps existing heavy-metal limits in force.
PFAS is sometimes used in release liners, coatings, or specialty films adjacent to blister packaging - worth auditing even where it's not the primary compliance driver.
The PPWR Declaration of Conformity: What It Actually Requires

The PPWR Declaration of Conformity is the single most immediate, non-negotiable requirement for pharma packaging teams right now. Unlike the recyclability design criteria (which phase in through 2028–2030), the DoC obligation applies with no transition period from 12 August 2026.

In practice, this means every packaging format - including each blister foil configuration in use - needs documentation showing:

Which PPWR requirements apply to that specific packaging
Evidence of compliance (or a justified, documented exemption)
Traceable ownership across procurement, quality, and regulatory functions

Companies without this in place risk exclusion from the EU market on that packaging format, regardless of company size - PPWR does not carve out small or micro enterprises, and it applies to non-EU exporters selling into the EU too.

A Practical Starting Checklist

Map every blister foil format currently on the market and flag which ones are direct-contact vs. secondary packaging
Confirm the recycled-content exemption applies and document why
Begin (or accelerate) mono-material and lightweighting evaluations for high-volume SKUs
Audit for PFAS in laminates, coatings, and liners
Assign clear ownership for the Declaration of Conformity across quality, regulatory, and packaging teams
Track national EPR registration separately - PPWR doesn't replace it
Frequently Asked Questions

Is pharmaceutical packaging exempt from PPWR?

No, not broadly. It has narrow exemptions, primarily from minimum recycled-content requirements for direct-contact packaging. Other obligations - substance restrictions, the Declaration of Conformity, and future recyclability criteria - still apply.

Does PPWR apply to blister foil?

Yes. Blister foil is generally treated as primary/immediate packaging, so it's exempt from recycled-content rules, but it must still meet the Declaration of Conformity requirement and will likely face pressure from future recyclability design criteria.

What's the PPWR deadline for pharma companies?

12 August 2026 for general application and the Declaration of Conformity. Design-for-recycling criteria are expected around 2028, with recycled-content and recyclability grading rules following through 2030.

Is aluminium blister foil recyclable under PPWR?

Standard PVC/aluminium blister laminates are difficult to recycle due to their multi-material structure, which is why mono-material alternatives (all-PP or all-aluminium) are gaining attention ahead of future recyclability grading.

Publish Your Article